Major players in the diabetes space could join forces as Dexcom (Nasdaq:DXCM) is reportedly in discussions to acquire Insulet (Nasdaq:PODD). Bloomberg reported today that people “with knowledge of the matter” have said talks are ongoing over a potential acquisition and even said an agreement could be reached “in the coming weeks.” Bloomberg’s sources preferred to remain anonymous […]
Insulet
Here’s what’s next for Insulet after the launch of Omnipod 5, CEO change
The future for Insulet (Nasdaq:PODD) has a different look than it did about a week ago. A massive shake-up at the executive level came on May 5 when Shacey Petrovic announced she would step down as president and CEO for personal reasons. Petrovic will stay on as a board member at the Acton, Massachusetts-based automated insulin […]
Shacey Petrovic to step down as Insulet CEO, ResMed exec Jim Hollingshead to take role
Insulet (Nasdaq:PODD) announced today that President and CEO Shacey Petrovic will step down for personal family reasons. Petrovic will step down from her position effective June 1, 2022, but will continue to serve on the company’s board. She will also serve as an advisor to the company through May 2023 to support the leadership transition to […]
Insulet posts Street-beating Q1 as Omnipod 5 rollout is ‘progressing very well’
Insulet (Nasdaq:PODD) shares were down after hours despite first-quarter results that topped the consensus forecast. The Acton, Massachusetts-based automated insulin technology developer posted profits of $27.8 million, or 40¢ per share, on sales of $295.4 million for the three months ended March 31, 2022, for a big bottom-line gain from breakeven this time a year ago […]
CGMs, insulin pumps and more: the biggest diabetes news to come out of ATTD 2022
All kinds of technologies were on display at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona last week. From continuous glucose monitoring (CGM) to automated insulin delivery, with plenty in between, a number of companies shared positive data for their diabetes offerings. Here are five of the biggest stories to come out […]
Insulet announces positive study data for Omnipod 5 for type 1, type 2 diabetes
Insulet (Nasdaq:PODD) today unveiled study results for the new Omnipod 5 automated insulin delivery system in type 1 and type 2 diabetes. Acton, Massachusetts-based Insulet presented results from studies as well as user experience data for both type 1 and type 2 diabetes at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona, Spain. […]
How Insulet created its next-gen Omnipod 5
Insulet (NSDQ:PODD) added to its portfolio of life-changing diabetes management technologies when its Omnipod 5 received FDA clearance in January. Omnipod 5 provides easier glucose management, with no multiple daily injections, no tubes and zero fingersticks. Paired with Dexcom’s G6 continuous glucose monitoring (CGM) system, Omnipod 5 is the first tubeless, wearable, automated insulin delivery […]
Diabetes tech is off to a hot start in 2022
Diabetes technology developers have high hopes for the year ahead, some of which have already come to fruition. Change is continuous in continuous glucose monitoring (GCM), with expanded wear-times, improved accuracy and more. Meanwhile, never-ending innovation in insulin delivery is delivering wearable patches and closedloop delivery systems, making insulin management easier for people with diabetes. […]
Insulet posts Street-beating Q4 with Omnipod revenues up nearly 20% from 2020
Insulet (NSDQ:PODD) this evening reported fourth-quarter results that came in ahead of the Wall Street consensus forecast amid strong sales growth. The Acton, Massachusetts–based maker of Omnipod insulin delivery systems posted profits of $29.2 million, or 42¢ per share, on sales of $307.7 million for the three months ended Dec. 31, 2021, for a massive […]
Insulet, Nintendo use ‘Animal Crossing’ video game to promote inclusivity for diabetes community
Insulet (NSDQ:PODD) announced today that new features set to debut on Nintendo’s Animal Crossing video game are inspired by people with diabetes. Acton, Massachusetts-based Insulet aims to promote representation and inclusion for the diabetes community through an activation on Animal Crossing: New Horizons. Get the full story at our sister site, Drug Delivery Business News.
Insulet appoints Elizabeth Weatherman to board of directors
Insulet (NSDQ:PODD) announced that Elizabeth (Bess) Weatherman was appointed to its board of directors. Weatherman — a veteran dealmaker in the health technology space — will stand for election by stockholders at the company’s 2022 annual meeting and has been named to the board’s Compensation Committee. Get the full story at our sister site, Drug Delivery […]
